RenovoRx (RNXT) IPO Opens Modestly Lower

Today's IPO for RenovoRx (NASDAQ: RNXT) opened for trading at $8.25 after pricing 1,850,000 units at a public offering price per unit of $9.00.

Roth Capital Partners is acting as the sole book-running manager for the offering. Maxim Group LLC is acting as lead manager for the offering.

RenovoRx, a biopharmaceutical company headquartered in Silicon Valley, California, has developed a therapy platform targeting difficult-to-treat tumors. Targeted therapy via the proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) platform safely and without transmission to non-targeted areas, is the primary focus.

You May Also Be Interested In

• Allarity Therapeutics files SPAC registration for $100M IPO
• Nscale seeks about $3.5 billion pre-IPO funding, source says
• Holtec Nuclear launches IPO roadshow, targets up to $18 per share